Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from Opyl Ltd. ( (AU:OPL) ) is now available.
Opyl Limited has announced strategic collaborations with Cardialysis and Evestia Clinical Limited to integrate its AI-enabled platform, TrialKey.ai, into their clinical trial processes. These partnerships aim to expand TrialKey’s global dataset and enhance its AI capabilities, thereby improving protocol feasibility, endpoint optimization, and predicted success rates in cardiovascular, oncology, and rare disease trials. The collaborations are expected to accelerate TrialKey’s commercial rollout, potentially leading to recurring revenue and strengthening Opyl’s market position in the healthcare technology sector.
More about Opyl Ltd.
Opyl Limited operates in the healthcare technology industry, focusing on AI-enabled solutions for clinical trial design. Its primary product, TrialKey.ai, aims to enhance clinical trial processes by expanding global datasets and refining AI engines through real-world collaborations. The company targets the cardiovascular, oncology, and rare disease sectors to improve trial outcomes and protocol designs.
Average Trading Volume: 313,543
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$4.93M
Find detailed analytics on OPL stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue